Commentary on the next two abstracts follows the second abstract. Suppression of prostate cancer induced bone remodeling by the endothelin receptor A antagonist atrasentan. Nelson JB, Nabulsi AA, Vogelzang NJ, Breul J, Zonnenberg BA, Daliani DD, Schulman CC, Carducci MA, Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, MD - J Urol 2003;169:1143-1149

By Trump D.L.  

Urologic Oncology: Seminars and Original Investigations, Vol. 21, Iss. 5, 2003-09 ,pp. : 410-410

Elsevier

Access to resources Recommend Favorite

The evolving role of docetaxel in the management of androgen independent prostate cancer - Khan MA, Carducci MA, Partin AW, Urological Institute, Johns Hopkins Hospital, Baltimore, MD. Journal of Urology 2003;170:1709-1716

By Chatta G.  

Urologic Oncology: Seminars and Original Investigations, Vol. 21, Iss. 6, 2003-11 ,pp. : 489-490

Elsevier

Access to resources Recommend Favorite

Allogeneic stem-cell transplantation of renal cell cancer after nonmyeloablative chemotherapy: feasibility, engraftment, and clinical results. Rini BI, Zimmerman T, Stadler WM, Gajewski TF, Vogelzang NJ, University of California San Francisco, Comprehensive Cancer Center, San Francisco, CA - J Clin Oncol 2002;20:2017-2024

By Trump D.L.  

Urologic Oncology: Seminars and Original Investigations, Vol. 21, Iss. 5, 2003-09 ,pp. : 412-413

Elsevier

Access to resources Recommend Favorite

A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, Chin JL, Vinholes JJ, Goas JA, Chen B, Zoledronic Acid Prostate Cancer Study Group, Uro-Oncology Clinic, Centre Hospitalier de l'Universite, de Montreal, Hopital Notre-Dame, Montreal, Quebec, Canada - J Natl Cancer Inst 2002;94:1458-1468

By Trump D.L.  

Urologic Oncology: Seminars and Original Investigations, Vol. 21, Iss. 5, 2003-09 ,pp. : 408-408

Elsevier

Access to resources Recommend Favorite

Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models. Denmeade SR, Sokoll LJ, Dalrymple S, Rosen DM, Gady AM, Bruzek D, Ricklis RM, Isaacs JT, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231 - Prostate 2003;54(4):249-257

By Bosland M.  

Urologic Oncology: Seminars and Original Investigations, Vol. 21, Iss. 5, 2003-09 ,pp. : 414-415

Elsevier

Access to resources Recommend Favorite